InterCure is a medical device company focused on respiratory treatment that has developed and patented a technology platform.
InterCure is a medical device company that has developed and patented a technology platform for respiratory-based treatment of cardiovascular and pulmonary diseases.The Company has incorporated its "Interactive Respiratory-Pacing" technology platform into several product lines, the first two of which offer a new therapeutic class of non-drug treatments for two of the most widespread and costly disease states in the healthcare industry: hypertension and heart failure.InterCure’s first market-ready product, RESPeRATE, is the only FDA-cleared, medical device clinically proven to lower high blood pressure with no side effects.InterCure's heart failure product, InTone™ has successfully completed phase 2a efficacy clinical trials and is expected to be launched when it completes the regulatory approval process.With its outstanding management team, the board of directors and a world-class Scientific Advisory Board, Intercure is poised to become the market leader in patient-focused medical devices that provide non-drug, no-side-effect treatment for some of the world's most prevalent and costly chronic conditions.InterCure was founded in 1994 and is headquartered in Ra'anana, Israel.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 11, 2021 | Post-IPO Equity | $8M | 1 | ARK Investment Management | — | Detail |
Nov 1, 2018 | Post-IPO Equity | $17.50M | 2 | GMF Capital | — | Detail |
Oct 27, 2011 | IPO | — | — | — | — | Detail |
Apr 13, 2005 | Series C | $3M | 2 | — | — | Detail |
Oct 30, 2001 | Series B | $4.50M | 6 | Medica Venture Partners | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Dec 23, 2015
Fore Biotherapeutics
|
Series Unknown | $10M | Biotechnology | Yes |
Investor Name | Lead Investor | Funding Round |
---|---|---|
ARK Investment Management | Yes | Post-IPO Equity |
GMF Capital | Yes | Post-IPO Equity |
Adam Neumann | — | Post-IPO Equity |
Medica Venture Partners | — | Series C |
Nippon Venture Capital | — | Series C |
Arie Ovadia | — | Series B |
Daniel Plotkin | — | Series B |
Mizrahi Tefahot Bank | — | Series B |
Palladin Consumer Retail Partners | — | Series B |
True North Partners | — | Series B |